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Abstract
Background: Placental Plasmodium falciparum malaria can trigger intervillositis, a local inflammatory response more
strongly associated with low birthweight than placental malaria infection alone. Fetal growth (and therefore
birthweight) is dependent on placental amino acid transport, which is impaired in placental malaria-associated
intervillositis. Here, we tested the hypothesis that mechanistic target of rapamycin (mTOR) signaling, a pathway
known to regulate amino acid transport, is inhibited in placental malaria-associated intervillositis, contributing to
lower birthweight.
Methods: We determined the link between intervillositis, mTOR signaling activity, and amino acid uptake in tissue
biopsies from both uninfected placentas and malaria-infected placentas with and without intervillositis, and in an in
vitro model using primary human trophoblast (PHT) cells.
Results: We demonstrated that (1) placental mTOR activity is lower in cases of placental malaria with intervillositis,
(2) placental mTOR activity is negatively correlated with the degree of inflammation, and (3) inhibition of placental
mTOR activity is associated with reduced placental amino acid uptake and lower birthweight. In PHT cells, we
showed that (1) inhibition of mTOR signaling is a mechanistic link between placental malaria-associated intervillositis
and decreased amino acid uptake and (2) constitutive mTOR activation partially restores amino acid uptake.
Conclusions: Our data support the concept that inhibition of placental mTOR signaling constitutes a mechanistic link
between placental malaria-associated intervillositis and decreased amino acid uptake, which may contribute to lower
birthweight. Restoring placental mTOR signaling in placental malaria may increase birthweight and improve neonatal
survival, representing a new potential therapeutic approach.
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Background
One in six infants worldwide are born with low birthweight
(<2500 g), which is the main risk factor underlying 80% of
neonatal deaths [1]. The World Health Organization reaf-
firmed reducing the prevalence of low birthweight by 30%
by 2025 as a global health priority. Malaria in pregnancy
is a leading cause of low birthweight and is responsible
for ~900,000 low birthweight deliveries and ~200,000
infant deaths annually [2]. Despite control measures,
Plasmodium falciparum malaria still affects about 85
million pregnancies each year [3]. Little is known about
the mechanistic link between malaria in pregnancy and
low birthweight.
Malaria in pregnancy can lead to placental malaria
characterized by the sequestration of P. falciparum-in-
fected erythrocytes in the maternal intervillous blood
space of the placenta. This can trigger the recruitment and
activation of maternal immune cells, resulting in a local
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malaria-associated intervillositis is more strongly associ-
ated with low birthweight than placental malaria without
intervillositis [4]. The underlying mechanisms linking
placental malaria-associated intervillositis and decreased
birthweight are unknown, which hinders the development
of intervention strategies aimed at improving the birth-
weight of infants born to malaria-infected women. Current
malaria control strategies such as insecticide-treated bed
nets, intermittent preventative malaria treatment of preg-
nant women, and supplementation of their diet have lim-
ited efficacy at improving birthweight [5, 6]. There is a
significant and urgent need for additional interventions
aimed directly at improving birthweight that can comple-
ment existing malaria control strategies.
Placental nutrient transfer controls fetal nutrient avail-
ability, which is a key determinant of fetal growth (and
therefore birthweight). The placental capacity to transfer
nutrients is highly dependent on the expression and
function of nutrient transporters in the syncytiotropho-
blast (the nutrient transporting epithelium of the human
placenta) [7]. System A is a group of amino acid trans-
porters that mediate the uptake of non-essential neutral
amino acids. Decreased placental System A activity has
been associated with decreased birthweight both in
humans [8, 9] and in animal models [10, 11]. Import-
antly, the magnitude of the decrease in placental System
A activity correlates with the severity of fetal growth re-
striction in women [8] and placental System A activity is
decreased before fetal growth restriction is observed in
animal models [10, 11]. This suggests that downregulation
of placental System A activity directly contributes to re-
duced birthweight. We previously demonstrated that pla-
cental malaria-associated intervillositis reduced both the
expression and activity of System A transporters, and that
System A activity and birthweight are positively correlated
in placental malaria [12]. However, the mechanism(s) by
which placental malaria-associated intervillositis impacts
placental System A activity is unknown.
The mechanistic target of rapamycin (mTOR) signal-
ing pathway is a nutrient-sensing pathway that regulates
cell growth, proliferation, and metabolism in response
to hormones, growth factors, and nutrient availability
(Additional file 1: Table S1). It exists as two protein
complexes: mTOR complex 1 (mTORC1), the master
regulator of protein translation and cell growth and
proliferation; and mTOR complex 2 (mTORC2), which
regulates cytoskeletal organization and cellular metabol-
ism. mTOR is expressed in the placental syncytiotropho-
blast where it regulates amino acid uptake by influencing
the trafficking of transporters to the plasma membrane
[13]. Upstream signals such as amino acids, growth fac-
tors, free fatty acids, oxygen, and cytokines have been
shown to influence placental mTOR signaling activity
[14, 15]. In animal models, placental mTOR inhibition
was associated with decreased placental amino acid
transport [11]. Similar findings were observed in human
fetal growth restriction of causes unrelated to placental
malaria [16]. These data suggest that placental mTOR
signaling influences fetal growth and birthweight by
regulating transplacental nutrient transport in response
to maternal signals.
Here, we provide for the first time evidence that inhib-
ition of mTOR signaling is a mechanistic link between
placental malaria-associated intervillositis and decreased
amino acid transport, contributing to lower birthweight.
Our findings open novel avenues of research to develop
interventions targeting placental mTOR signaling to im-
prove birthweight and neonatal health in malaria-exposed
populations.
Methods
Detailed materials and methods can be found in Additional
file 1.
Collection of placental samples
The College of Medicine Research Ethics Committee,
University of Malawi, approved this study. Written in-
formed consent was obtained from primiparous Malawian
women. Placental villous tissue biopsies collected after
delivery were grouped based on histology as described
previously [4]: uninfected (no malaria, no intervillositis),
placental malaria without intervillositis, and placental mal-
aria with intervillositis. Table 1 summarizes the clinical
characteristics of the study subjects.
Primary trophoblast cell culture
Placental villous tissue samples were collected from
healthy women with normal term pregnancies following
written informed consent as approved by the Colorado
Multiple Institutional Review Board (COMIRB-14-1073).
Primary human trophoblast (PHT) cells were isolated by
trypsin digestion and Percoll centrifugation as originally
described [17] with modifications [18]. Syncytialization
was assessed by human chorionic gonadotropin secre-
tion. Cell viability was assessed by lactate dehydrogenase
release.
Monocyte-conditioned media
Conditioned media were prepared as previously described
[12] with modifications. CD14+ cells were cultured in 1:1
mixture of Dulbecco’s modified Eagle’s medium (DMEM,
Sigma-Aldrich) and Ham’s F-12 nutrient mixture (Invitro-
gen) supplemented with 10% fetal bovine serum and with
penicillin/streptomycin.
Small interfering RNA transfection
PHT cells were transfected with 10 nM DEPTOR small
interfering RNA (siRNA; SASI_Hs01_00204344, Sigma-
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Aldrich) or with Scramble siRNA control using Lipofecta-
mine RNAiMax transfection reagent (Thermo Scientific)
according to the manufacturer’s protocol.
Amino acid uptake
System A activity was assessed by measuring the
Na+-dependent uptake of 14C-methyl-aminoisobutyric
acid (MeAIB) as previously described [13].
Western blot
Placental homogenates and PHT cell lysates were loaded
and proteins separated on 4–12% Bis-Tris gels (Invitro-
gen) or 12% Mini-Protean protein gels (Bio-Rad) and
transferred onto 0.20-μm nitrocellulose membrane (GE
Healthcare) or polyvinylidene fluoride membrane (Bio-
Rad). Membranes were incubated with primary antibodies:
rabbit anti-4EBP-1, anti-phospho-4EBP-1 (Thr37/46), anti-
ribosomal protein S6, anti-phospho-ribosomal protein S6
(Ser235/236), anti-Akt, anti-phospho-Akt (Ser473), and mouse
anti-β-actin (Sigma-Aldrich). Horseradish peroxidase-
conjugated secondary anti-rabbit and anti-mouse anti-
bodies (Cell Signaling) were used as secondary antibodies.
Proteins were visualized using chemiluminescence detec-
tion. Densitometry was performed using NIH’s ImageJ
software.
Cytokine analysis
Cytokine profiles in monocyte-conditioned media were
analyzed by a multiplexed bead-based immunoassay
using a panel of antibodies against human inflammatory
cytokines (BD Biosciences) according to manufacturer’s
instructions.
Data presentation and statistical analysis
Data are presented as medians and scatter plots or me-
dians and inter-quartile range. Data were analyzed and
graphs designed using Prism 5 software (Graph Pad).
Two-group comparisons were made using Mann–Whitney
test and three-group comparisons using Kruskal–Wallis
test. Spearman’s correlation test was used to assess correla-
tions with 95% confidence interval.
Results
Placental mTOR signaling is inhibited in placental
malaria-associated intervillositis
We aimed to assess the impact of P. falciparum infection
and intervillositis on mTOR signaling in human placenta
using well-established mTOR functional readouts as sum-
marized in Additional file 1: Table S1. Placental mTOR
signaling activity was measured by quantifying the ratio
of phosphorylated-to-total protein expression levels of
downstream targets of both mTORC1 (rpS6Ser235/236
and 4E-BP1Thr37/46) and mTORC2 (AktSer473) (Fig. 1a).
The activity of both mTORC1 and mTORC2 (Fig. 1b)
was lower in women with placental malaria-associated
intervillositis compared to uninfected placentas (rpS6:
P = 0.01; 4EBP-1: P = 0.03; Akt: P = 0.0006) and to in-
fected placentas without intervillositis for Akt signaling
(Akt: P = 0.02). These results are consistent with a causal
Table 1 Clinical characteristics of study subjects
Uninfected Placental malaria without intervillositis Placental malaria with intervillositis P value
Subjects 17 7 14
Age (years) 19 18 20 0.61
(18–19) (17–21) (18–21)
Gestational age (weeks) 40 40 40 0.87
(38–40) (38–40) (38–40)
Maternal weight at enrollment (kg) 56 56 56 0.77
(49.5–58.5) (52–60) (52–56)
Percentage of monocytes 0 2.2 8.6 0.0001
(1.2-3) (6.6–10.8)
Parasitemia (%) 0 0.41 1.2 0.0001
(0.21–0.83) (0.66–11.2)
Birthweight (kg) 3.0 2.8 2.9 0.54
(2.7–3.5) (2.6–3.1) (2.6–3.0)
Placental weight (g) 500 530 495 0.80
(430–550) (460–560) (420–580)
Fetal-to-placental weight ratio 5.95 5.71 5.89 0.48
(5.2–6.48) (4.11–6.09) (5.26–6.20)
Values are presented as median and interquartile range
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link between placental malaria-associated intervillositis
and inhibition of mTOR signaling. This was further sup-
ported by the negative correlation between mTOR signal-
ing activity and the severity of intervillositis measured as
the percentage of monocytes in the intervillous space
(Table 2 and Additional file 2: Figure S1).
Inhibition of placental mTOR signaling is associated with
impaired amino acid transport and reduced birthweight
Inhibition of mTOR signaling may lead to reduced birth-
weight by impacting amino acid transport. We determined
the relationship between placental mTOR signaling activity,
amino acid transport, and birthweight. mTOR signaling
Fig. 1 Placental malaria with intervillositis is associated with inhibition of placental mTOR signaling. mTOR activity was determined as the
phosphorylated-to-total protein expression levels of rps6, 4EBP-1, and Akt in placentas grouped into uninfected (n = 17), placental malaria
without intervillositis (n = 7), and placental malaria with intervillositis (n = 14). a Representative Western blot. b mTOR signaling activity is
inhibited in placental malaria with intervillositis. PM placental malaria, IV intervillositis
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showed a positive correlation with our previous microvillous
plasma membrane amino acid uptake data [12] measured as
System A activity (Table 2 and Additional file 2: Figure S1).
This is consistent with our previous reports demonstrating
that mTOR signaling is a major regulator of placental Sys-
tem A activity [19, 20], an important contributor to fetal
growth. Importantly, we found a positive correlation be-
tween mTOR signaling activity and birthweight (Table 2
and Additional file 2: Figure S1). Birthweight was also mar-
ginally positively correlated with the degree of intervillositis
(n = 38; r = −0.27; P = 0.093). Collectively, these data are
consistent with the model that placental malaria-associated
intervillositis decreases placental mTOR signaling, which re-
duces amino acid uptake and birthweight.
Intervillositis inhibits mTOR signaling and System A
amino acid transport activity in cultured primary human
trophoblast cells
To establish a causal link between inhibition of mTOR
signaling and reduced System A activity in placental
malaria-associated intervillositis, we adapted our pub-
lished protocol for studies of placental responses to pla-
cental malaria-associated intervillositis in BeWo cells for
use in PHT cells [12]. Placental malaria-associated inter-
villositis was modeled using the conditioned medium
from a monocyte/P. falciparum-infected erythrocyte co-
culture (herein “infected conditioned medium”). This
conditioned medium displayed high levels of inflamma-
tory cytokines such as IL-1β, IL-6, IL-8, TNF, and IL-10
(Additional file 3: Figure S2). Conditioned medium from
a monocyte/uninfected erythrocyte co-culture (herein
“uninfected conditioned medium”) and culture medium
(herein “control”) were used as controls.
Both mTORC1 and mTORC2 signaling activity were
significantly lower in PHT cells exposed to infected
conditioned medium compared to PHT cells exposed to
uninfected conditioned medium (4EBP-1: P = 0.04; Akt:
P = 0.09) or to control medium (rps6: P = 0.01; 4EBP-1:
P = 0.008; Akt: P = 0.002) (Fig. 2). This inhibition of
mTOR signaling activity was paralleled by reduced Sys-
tem A activity in PHT cells exposed to infected condi-
tioned medium compared to PHT cells exposed to
uninfected conditioned medium (P = 0.04) or to control
medium (P = 0.03) (Fig. 2c). The viability of PHT cells
was unaffected by exposure to infected conditioned
media (Additional file 4: Figure S3). Collectively, these
data are in agreement with our observations in women
with placental malaria (Fig. 1), supporting the hypothesis
placental malaria-associated intervillositis inhibits mTOR
signaling, which results in reduced System A activity.
Activation of mTOR signaling partially restores System A
activity in response to placental malaria-associated
intervillositis
To firmly establish placental mTOR signaling inhibition as
a mechanistic link between placenta malaria-associated
intervillositis and reduced System A activity, we deter-
mined the effect of constitutive mTOR signaling activation
on System A activity in PHT cells exposed to infected
conditioned medium. To constitutively activate mTOR
signaling, we silenced DEPTOR, the endogenous in-
hibitor of mTOR [21], using siRNA. DEPTOR silencing
reduced DEPTOR protein expression by approximately
40% (P = 0.004) (Fig. 3a) without affecting cell differen-
tiation and viability (Additional file 4: Figure S3). As
expected, DEPTOR silencing significantly increased
mTORC1 signaling activity (rps6: +44%, P = 0.008; 4E-
BP1: +60%, P = 0.004; Figs 3b, c) and upregulated System
A activity (+66%, P = 0.009; Fig. 3d) [13]. This is consistent
with previous reports that silencing of DEPTOR activates
mTORC1 [21].
We quantified the decrease in System A activity in-
duced by the infected conditioned medium in PHT cells
transfected with DEPTOR siRNA versus PHT cells trans-
fected with Scramble siRNA. In cells transfected with
Scramble siRNA, System A activity decreased by 72% in
response to the infected conditioned medium whereas
System A activity in DEPTOR-silenced cells was decreased
by only 50% (Fig. 3e). This demonstrated that mTOR sig-
naling activation by DEPTOR silencing attenuated the in-
hibition of System A activity in response to infected
conditioned medium by approximately 30% (P = 0.004).
This suggests that placental mTOR activation could par-
tially restore placental amino acid uptake in response to
placenta malaria-associated intervillositis.
Discussion
Reducing the incidence of low birthweight remains a global
health priority to minimize neonatal morbidity and mortal-
ity, impaired infant growth and cognitive development, and
Table 2 Correlation between mTOR signaling activity and
percentage of monocyte, amino acid uptake and birthweight
mTOR signaling activitya
rps6 4EBP-1 Akt
Monocytes (%) r = −0.34 r = −0.34 r = −0.59
(−0.60 to −0.02) (−0.60 to −0.02) (−0.77 to −0.32)
P = 0.01 P = 0.01 P = 0.0001
Amino acid uptake
(System A activity)
r = 0.28 r = 0.40 r = 0.44
(−0.07 to 0.57) (0.07 to 0.65) (0.12 to 0.68)
P = 0.04 P = 0.008 P = 0.004
Birthweight r = −0.03 r = 0.27 r = 0.25
(−0.36 to 0.30) (−0.07 to 0.55) (−0.08 to 0.54)
P = 0.42 P = 0.05 P = 0.05
Correlation analyses are presented as r score and 95% confidence interval. These
analyses include all participants (n = 38).
aPhosphorylated-to-total protein expression ratio
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chronic diseases later in life [22]. Understanding the
pathogenesis of reduced birthweight in placental mal-
aria will provide the foundation for the development of
novel interventions that complement existing malaria
control approaches to directly improve fetal growth
and prevent poor neonatal and pregnancy outcomes. In
this study, we provide the first evidence for a role of
placental mTOR signaling in decreased placental amino
acid uptake and lower birthweight in placental malaria-
associated intervillositis. Specifically, we demonstrate
that mTOR signaling is inhibited in placental malaria-
associated intervillositis and in cultured PHTcells exposed
to malaria-infected conditioned media. Furthermore,
we provide evidence that mTOR signaling inhibition
mechanistically links intervillositis to decreased amino
acid transport.
The mTOR signaling pathway has been proposed to
play a central role in placental nutrient sensing [23]. This
model proposes that the placenta regulates its nutrient
transport function to match maternal supply and fetal de-
mand by responding to upstream maternal signals and
modulating placental function, including transplacental
amino acid transport [23, 24]. In placental malaria-
associated intervillositis, maternal mononuclear cells acti-
vated by infected erythrocytes in the intervillous space re-
lease inflammatory mediators that create a distinct milieu
characterized by elevated levels of cytokines and chemo-
kines such as IFN-γ, TNF, IL-10, MCP-1, MIP-1α, IL-8,
CCL2, and CCL3 [25–27]. Some of these circulating
inflammatory mediators could be responsible for the
inhibition of placental mTOR signaling we observed in
the placentas of women with placental malaria with inter-
villositis. The key role of intervillositis in causing inhib-
ition of placental mTOR signaling is supported in our
current study by the strong negative correlation between
mTOR signaling activity and the degree of intervillositis.
Our ex vivo results reported here and in our previous
publication [12] have demonstrated that placental malaria-
Fig. 2 Placental mTOR signaling inhibition in an in vitro model of placental malaria-associated intervillositis. mTOR activity was determined as the
phosphorylated-to-total protein expression levels of rps6, 4EBP-1, and Akt in primary human trophoblast cells exposed to infected conditioned
medium, uninfected conditioned medium, and culture medium alone. a Representative Western blot. b mTOR signaling activity and c System A
activity are decreased in primary human trophoblast cells exposed to infected conditioned medium. n = 4 placentas. CM conditioned medium,
Control culture medium alone
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associated intervillositis is specifically associated with im-
paired System A activity and that placental malaria itself
(i.e., in the absence of intervillositis) is not associated with
impaired System A activity. Also, we showed in our previ-
ous publication [12] that infected erythrocytes, either in-
tact or lysed, did not impact on System A activity. These
collective observations argue for a limited role (if any) of
placental malaria per se on impaired System A activity. As
such, we elected not to include a parasite-conditioned
medium control. We attempted to model the unique mi-
lieu in the intervillous space of women with placental mal-
aria-associated intervillositis using conditioned medium
from a co-culture of monocytes and P. falciparum-infected
erythrocytes. This conditioned medium displayed high
levels of IL-1β, IL-6, IL-8, TNF, and IL-10. Cytokines such
as IL-1β have been shown to inhibit mTOR activity [28]
and similar cytokine profiles have been reported in malaria-
infected pregnant women [26, 29]. The relevance of our in
vitro model is further reinforced by the use of PHT cells,
which undergo differentiation to form multinucleated syn-
cytial islands in culture. We recapitulated the findings in
women with placental malaria in this cell culture model,
providing support for the concept that placental mTOR
signaling inhibition mechanistically links placental malaria-
associated intervillositis with decreased amino acid uptake.
mTORC1 is the master regulator of the translational
machinery and activates protein synthesis by phosphor-
ylating downstream targets including 4EBP-1 (Additional
file 1: Table S1). Both in placental tissue obtained from
women with placental malaria and in cultured PHT cells,
we observed that placental malaria-associated intervillosi-
tis consistently inhibited phosphorylation of 4EBP-1 but
not that of ribosomal protein S6 (rps6), an indirect target
of mTORC1. This may be because 4EBP-1 lies directly
downstream of mTORC1, unlike rps6. Reduced 4EBP-1
phosphorylation prevents protein translation initiation, de-
creasing protein synthesis [30]. Similar to our findings, hu-
man fetal growth restriction due to placental insufficiency
unrelated to placental malaria is associated with a marked
inhibition of 4EBP-1 phosphorylation [16], which could
decrease protein synthesis. We speculate that inhibition of
placental protein synthesis as a result of inhibition of
mTOR signaling further contributes to restricted fetal
growth in placental malaria-associated intervillositis.
We also observed that placental malaria-associated
intervillositis decreased the phosphorylation of Akt, an
Fig. 3 Constitutive mTOR activation by DEPTOR silencing partially restores System A activity. a Protein expression of DEPTOR (an endogenous
mTOR inhibitor) was decreased following DEPTOR silencing in primary human trophoblast cells. mTOR activity was measured as the
phosphorylated-to-total protein expression levels of rps6, 4EBP-1, and Akt in primary human trophoblast cells transfected either with DEPTOR
siRNA or with a Scramble siRNA control (SCR). b Representative Western blot. DEPTOR silencing resulted in (c) constitutively higher mTORC1
signaling activity only and (d) higher System A activity. e DEPTOR silencing partially restored System A activity in response to infected conditioned
medium. n = 5 placentas. CM conditioned medium, SCR scrambled
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mTORC2 target, to a greater extent than that of mTORC1
targets. Endoplasmic reticulum (ER) stress inhibits Akt
phosphorylation [31, 32] and has been reported in the pla-
centa of non-malaria cases of fetal growth restriction [16].
In placental malaria-associated intervillositis, the inflamma-
tory mediators present in the intervillous space could in-
duce syncytiotrophoblast ER stress [33], which may
contribute to placental mTORC2 signaling inhibition [31]
in addition to mTOR-dependent mechanisms. Given the
strong association between mTORC2 activity and System
A activity both ex vivo (Table 2, Additional file 2: Figure
S1) and in vitro in PTH cells [20], this greater mTORC2
signaling inhibition could explain the extent of System
A inhibition observed in placental malaria-associated
intervillositis [12].
We established mTOR signaling as a mechanistic link
between placental malaria-associated intervillositis and
reduced amino acid uptake using RNAi-mediated silen-
cing of DEPTOR, an endogenous mTOR inhibitor [21].
Knockdown of DEPTOR results in constitutive activation
of mTOR signaling [34]. In the current study, DEPTOR si-
lencing in PHT cells resulted in increased mTORC1 but
not mTORC2 signaling activity. This is in agreement with
Peterson and colleagues who established that knockdown
of DEPTOR was sufficient to activate mTORC1 but not
mTORC2 [21], causing an asymmetrical effect on mTOR
signaling [35]. However, we previously observed that DEP-
TOR silencing in PHT cells activated both mTORC1 and
mTORC2 [13]. Differences in the sequences of DEPTOR
siRNA used in these studies might underlie the differing
results. Given that placental malaria-associated intervillo-
sitis in the placentas of women with placental malaria and
in culture PHT cells appears to inhibit mTORC2 more
strongly than mTORC1, it is possible that most of the de-
crease in System A activity in response to placental
malaria-associated intervillositis is mediated by mTORC2.
The lack of significant effect of DEPTOR silencing on
mTORC2 signaling could therefore explain why DEPTOR
silencing only partly restored the decrease in System A ac-
tivity in response to infected conditioned media. Alterna-
tively, the partial restoration could also be due to the
incomplete silencing of DEPTOR following DEPTOR
siRNA transfection. Regardless, this finding suggests that
increasing placental mTOR signaling could upregulate the
uptake of amino acids, thereby improving birthweight.
Our results provide evidence for a causal link between
placental malaria-associated intervillositis, mTOR signaling
inhibition, and decreased amino acid uptake, an important
determinant of fetal amino acid availability and fetal
growth. The positive correlation between mTOR signaling
and birthweight further supports the hypothesis that pla-
cental mTOR signaling influences fetal growth. We chose
to focus on System A because this amino acid transporter
is regulated by mTOR and is the placental transporter
system most strongly associated with fetal growth [8]. Fur-
ther work should investigate whether other placental amino
acid transporters are inhibited in placental malaria-
associated intervillositis. Further, a detailed profiling of in-
flammatory mediators in the intervillous blood and the
conditioned media will help to identify factors that inhibit
placental mTOR signaling.
Our findings identify placental mTOR as a potentially
valuable target for interventions aimed at improving birth-
weight in malaria in pregnancy. There is strong interest in
targeting mTOR activity in therapeutic development and
various mTOR signaling regulators have recently been tested
in clinical trials for other conditions [36]. Some are already
used in the clinic [37, 38]. Further, recent studies provide
emerging evidence that activators of mTOR signaling can be
used to prevent or reverse fetal growth restriction of causes
other than placental malaria [39–49]. For example, late ges-
tation arginine treatment of women with unknown causes of
fetal growth restriction increased birthweight (177 to 328 g;
~10% of normal birthweight) and decreased incidence of
fetal growth restriction by 40–50% [41, 43]. Import-
antly, these interventions were conducted after the diag-
nosis of fetal growth restriction, suggesting that arginine
can rescue fetal growth. Leucine treatment (in combin-
ation with other branched-chain amino acids) has also
been repeatedly shown to improve fetal growth in various
species and models of fetal growth restriction [47–49]. For
example, leucine is essential for attenuating fetal growth
restriction caused by a protein restriction in rats [47] and
restores fetal weight in a mouse model of tumor-induced
fetal growth restriction [49]. Significantly, these studies
established that leucine supplementation also activated
placental mTOR signaling. We propose that restoring pla-
cental mTOR signaling in placental malaria would en-
hance placental amino acid uptake and improve fetal
growth and pregnancy outcomes, and should be further
investigated. This could be first done using our in vitro
model by testing mTOR activators for their capacity to re-
store amino acid uptake by PHT cells exposed to infected
conditioned media. Positive hits could then be further in-
vestigated in animal models of malaria in pregnancy [50].
Conclusions
Various malaria control measures have decreased malaria
prevalence but with limited impact on the birthweight of
babies born to malaria-infected women. Similarly, modest
gains in birthweight have been achieved using untargeted
maternal dietary supplementation [5, 6]. There is an ur-
gent need for a better understanding of the mechanisms
leading to low birthweight in malaria in pregnancy. This
will allow for the development of new interventions dir-
ectly aimed at improving birthweight that would be com-
plementary to existing malaria control measures. Here,
our data strongly suggest that inflammatory mediators in
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Fig. 4 Proposed mechanism for reduced birthweight in placental malaria-associated intervillositis. a Under normal physiological conditions,
upstream regulators of mTOR such as growth factors and hormones activate mTOR and its downstream effectors rps6, 4E-BP1, and Akt, which
promote the translocation of amino acid transporters to the microvillous plasma membrane, promoting transplacental amino acid transfer
and adequate fetal growth and birthweight. b In placental malaria-associated intervillositis, inflammatory mediators are released by monocytes
after phagocytosis of P. falciparum-infected erythrocytes, by rupture of infected erythrocytes, and by the syncytiotrophoblast in response to
the adhesion of infected erythrocytes. This inflammatory response inhibits mTOR signaling, reducing amino acid transport by decreasing the
translocation of amino acid transporters to the microvillous plasma membrane. This results in a suboptimal amino acid fetal supply and reduced fetal
growth and birthweight
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placental malaria-associated intervillositis inhibit placental
mTOR signaling, reducing placental amino acid transport,
which is likely to contribute to decreased birthweight
(Fig. 4). mTOR activation increases the surface abundance
of amino acid transporters in the plasma membranes of
the syncytiotrophoblast allowing for increased amino acid
transport [13], which may improve fetal growth and birth-
weight. This identifies placental mTOR as a potentially
valuable target for interventions aimed at improving birth-
weight in malaria in pregnancy.
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